

Katarzyna Bergmann, Jolanta Obczyńska\*, Grażyna Odrowąż-Sypniewska

Department of Laboratory Medicine, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland

\*A graduate of Laboratory Medicine, MSc

# Association of serum adiponectin and visfatin with body composition and selected biochemical cardiometabolic risk factors in non-obese individuals with normal fasting glycaemia

## Corresponding author:

Katarzyna Bergmann, PhD  
Department of Laboratory Medicine  
Nicolaus Copernicus University,  
Collegium Medicum in Bydgoszcz  
Skłodowskiej-Curie 9,  
85-799 Bydgoszcz, Poland  
Tel. +48 52 585 44 90,  
fax +48 52 585 36 03  
E-mail: [bergmann@vp.pl](mailto:bergmann@vp.pl)

## ABSTRACT

**Background:** Adipose tissue produces many metabolically active substances such as adiponectin and visfatin. Both have potential anti-inflammatory, anti-atherogenic, and increasing insulin sensitivity properties. We evaluated the diagnostic value of serum adiponectin and visfatin as potential cardiometabolic risk factors.

**Subjects and methods:** Sixty non-smoking, non-obese subjects aged 25–40 years with normal fasting glycaemia were included in the study. In all subjects serum fasting lipid profile, CRP, glucose, insulin, and apolipoprotein AI and B measurements were performed on an automatic analyser, while adiponectin and visfatin were measured using manual enzyme-linked immunosorbent assay (ELISA). Blood pressure measurements, body composition analysis using bioimpedance method (BIA), and basic anthropometric measurements (weight, BMI, WHR) were performed.

**Results:** In the study group the concentration of adiponectin and visfatin was significantly inversely and moderately related with the amount of visceral fat, BMI, and waist circumference, while an inverse weak relationship with HOMA-IR and insulin level was observed. Moreover, adiponectin was weakly inversely related with CRP but positively with HDL-C and apolipoprotein AI. The prevalence of subjects with CRP < 1 mg/L was significantly higher at the highest adiponectin and visfatin concentrations (third tertile). At the lowest adiponectin concentrations (first tertile) the percentage of subjects with elevated apoB  $\geq$  100 mg/dL was increased.

**Conclusion:** The relationship of serum adiponectin and visfatin with the amount of visceral fat, lipid profile, apolipoproteins, and CRP suggests their potential diagnostic value in the assessment of cardiometabolic risk. The predictive value of both adipocytokines should be confirmed in a large population-based study.

**Key words:** adiponectin, visfatin, obesity, metabolic syndrome, cardiometabolic risk

Med Res J 2017; 2 (4): 165–171

Medical Research Journal 2017;  
Volume 2, Number 4, 165–171  
10.5603/MRJ.2017.0023  
Copyright © 2017 Via Medica  
ISSN 2451-2591

## Introduction

According to the World Health Organisation, in 2005 around 1.6 billion people worldwide were overweight and more than 522 million were obese. Obesity is not only a medical problem, contributing to about 10–13% of premature deaths in Europe, but also economic problem. Costs related to the diagnosis and treatment of obesity in Europe range from 2 to 7% of financial outlays for health care [1]. In recent decades, research on adipose tissue has revealed a number of findings that have allowed adipose tissue to be qualified as an

endocrine organ. The discovery of leptin in 1994 was a breakthrough. Since then, many other substances derived from adipose tissue have been isolated, including adipocytokines, various cytokines, and proteins.

Particularly important is the role of adipocytes in the production of adipocytokines and cytokines that regulate systemic inflammation. These indicators are used in routine diagnostics of inflammation and infection. The most important markers of inflammation released from adipose tissue include: TNF- $\alpha$ , IL-6, IL-1 $\beta$ , and procalcitonin (PCT). Adipocytokines exhibit local and systemic pro- and anti-inflammatory effects. They

regulate metabolic and systemic processes and play a role in maintaining energy balance in glucose and lipid metabolism. They also participate in immune mechanisms and affect angiogenesis.

Numerous studies have confirmed a strong relationship between type 2 diabetes, metabolic syndrome, and cardiometabolic risk with changes in the level of adipocytokines. Among the most well-known adipocytokines are adiponectin, leptin, adiponectin, resistin, and visfatin.

In 2005, the gene for growth factor for early B cells (B-cell colony-enhancing factor, PBEF) was identified in visceral adipose tissue, and the product of this gene was called visfatin. Visfatin (PBEF, NAMPT) is a peptide composed of 491 amino acids [2]. It is produced in adipocytes and macrophages infiltrating adipose tissue and in some cancer cells. Secretion of visfatin fluctuates throughout the day with the highest concentration observed in the afternoon. Visfatin exerts a hypoglycaemic effect, which is because PBEF directly binds to the insulin receptor at a site other than insulin and promotes glucose uptake in tissues. Visfatin induces the process of differentiation of preadipocytes to adipocytes, and further stimulates the synthesis of proinflammatory cytokines, including IL-6 and IL-8. Its concentration is related to the level of oxidative stress [3].

Adiponectin composed of 244 amino acids constitutes about 0.01% of all plasma proteins. In women, its concentration is higher than in men [4]. It exhibits structural similarity to collagen type VIII and X, as well as to the complement fraction C1q. In blood, adiponectin occurs in three forms, differing in molecular weight: low molecular weight (trimer) — LMW, medium molecular weight (hexamer) — MMW, and high-molecular weight (built from 12-14 subunits) — HMW.

Adiponectin is derived primarily from adipocytes, but in small amounts from bone marrow cells, endothelial cells of the liver, and cardiomyocytes, and it is metabolised in the kidneys. Adiponectin is involved in many processes: organogenesis, inflammation, glucose metabolism, cell differentiation, and auto-immune reactions [5]. Adiponectin was proven to enhance insulin sensitivity by several mechanisms: increasing the oxidation and transport of free fatty acids, lowering blood glucose by reducing liver gluconeogenesis, inhibition of triglyceride deposition in adipose tissue, and decreasing TNF- $\alpha$  activity in adipose tissue and in macrophages located in the vascular endothelium [6]. Decreased adiponectin levels are observed in obesity, cardiovascular diseases, in subjects with insulin resistance, as well as in alcoholics and smokers [5].

We evaluated the relationship between serum adiponectin and visfatin concentration with body composition and various biochemical cardiometabolic risk factors in young non-obese normoglycaemic individuals.

## Subjects, materials, and methods

The study consisted of 60 non-obese (BMI < 30 kg/m<sup>2</sup>), non-smoking, and normoglycaemic (fasting glucose 60–99 mg/dL) subjects aged 25–40 years (30 women, 30 men). Basic anthropometric measurements (body weight, waist circumference, BMI, WHR) and blood pressure measurements with an automatic blood pressure monitor Omron M6 Comfort (Omron Healthcare, Kyoto, Japan) were performed and medical history of chronic diseases was obtained.

Serum and fluoride plasma were collected in the morning (7.00-9.00 a.m.) after 12-hour fast. Samples were centrifuged in low temperature (4°C). Laboratory tests: glucose, C-reactive protein (CRP), total cholesterol (TC), HDL-cholesterol (HDL-C), triglycerides (TG), and apolipoproteins AI and B (apoAI, apoB) were performed on an Architect ci8200 (Abbott Laboratories, Abbott Park, USA) directly after centrifugation. LDL cholesterol (LDL-C), non-HDL cholesterol (non-HDL-C), and atherogenic index (apoB:apoAI) were calculated. Serum samples were divided into small aliquots for further assays and frozen at -70°C to avoid peptides degradation. Concentration of serum adiponectin and visfatin was assayed using available commercial ELISA kits (Human Adiponectin RD195023100 BioVendor R&D; Visfatin C-Terminal [Human] EK-003-80, Phoenix Pharmaceuticals, Inc.). Detection limits were 0.26 ng/mL for adiponectin and 0.1 ng/mL for visfatin. All laboratory measurements were performed in the Department of Laboratory Medicine, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Poland.

Body composition (percentage of body fat, muscle, and visceral fat) was evaluated using a body segment analyser based on electrical bioimpedance (BIA) technology (InnerScan V BC-545N, Tanita). Measurements were performed in the fasting state, in the morning, directly before blood sampling, in accordance with the manufacturer's instructions [7]. The reference values of these parameters depended on age, and for 25–40-year-olds the following values were adopted: fat mass in women 21–33%, in men 8–20%; level of visceral fat 1–12; muscle mass in women > 24%, in men > 33% (according to manufacturer's manual).

Statistical analysis was performed using STATISTICA 12.0 PL software (StatSoft, Inc., 2014). Data were presented as mean  $\pm$  standard deviation (normal distribution) or median and 25<sup>th</sup>–75<sup>th</sup> percentile (non-Gaussian distribution). Differences between study groups were measured by t-Student, U-Mann-Whitney, and ANOVA Kruskal-Wallis tests. P values < 0.05 were considered statistically significant.

The study was approved by the Bioethics Committee at the NCU Collegium Medicum in Bydgoszcz, Poland (No. KB 627/2010) and complied with the World Medical

**Table 1.** Clinical characteristics of the study group.

VARIABLES	ALL (n = 60)	WOMEN (n = 30)	MEN (n = 30)	P W vs. M
Age (years)	30 (26–35)	29.5 (25–37)	30 (27–32)	ns
BMI (kg/m <sup>2</sup> )	22.7 ± 2.8	21.3 ± 2.3	24.1 ± 2.7	<0.001
Waist (cm)	80 (69.5–87.5)	70.5 (66–76)	87 (84–94)	<0.001
WHR	0.81 (0.75–0.88)	0.75 (0.73–0.79)	0.88 (0.84–0.89)	<0.001
SBP (mmHg)	123 ± 11	118 ± 10	129 ± 10	<0.001
DBP (mmHg)	84 ± 8	81 ± 9	86 ± 7	0.036
Fat mass (%)	24.4 ± 6.6	28.2 ± 5.4	20.6 ± 5.4	<0.001
Body mass (%)	51 ± 12.5	40 ± 3.3	61.9 ± 7.7	<0.001
Level of visceral fat	4.0 (2.3–6.0)	2.8 (1.5–4.0)	5.75 (4.0–8.0)	<0.001

Data presented as mean ± SD or median (25–75%)

ns- statistically insignificant (p &gt; 0.05)

SBP — systolic blood pressure, DBP — diastolic blood pressure

**Table 2.** Biochemical characteristics of the study group.

PARAMETER	ALL (n = 60)	WOMEN (n = 30)	MEN (n = 30)	P W vs. M
Glucose (mg/dL)	92 (88–96)	89 (85–93)	96 (92–99)	<0,001
CRP (mg/L)	0.5 (0.35–1.1)	0.5 (0.4–1.1)	0.6 (0.3–1.2)	ns
Insulin (μU/mL)	6.6 (5.1–9.0)	5.95 (5.24–7.36)	7.9 (5.0–10.4)	0.036
HOMA-IR	1.5 (1.1–2.1)	1.32 (1.1–1.6)	1.86 (1.2–2.4)	0.012
TC (mg/dL)	189.6 ± 35.8	186 ± 34	193 ± 38	ns
HDL-C (mg/dL)	55 ± 12	61 ± 11	48 ± 8	<0.001
TG (mg/dL)	82 (65–109)	74 (64–88)	99 (67–127)	0.014
LDL-C (mg/dL)	117 ± 32	109 ± 29	124 ± 33	ns
non- HDL-C (mg/dL)	135 ± 36	125 ± 30	145 ± 39	0.028
apoAI (mg/dL)	145 ± 23	158 ± 21	133 ± 17	<0.001
apoB (mg/dL)	78.0 ± 21	74 ± 16	82.8 ± 22.7	ns
apoB:apoAI	0.56 ± 0.19	0.47 ± 0.12	0.64 ± 0.21	<0.001
Adiponectin (ng/mL)	10 (8–17)	11 (9–17)	8.9 (6.7–16.6)	ns
Visfatin (ng/mL)	13 (8.3–22)	15.2 (8.7–26.6)	12 (8.3–19.7)	ns

Data presented as mean ± SD or median (25–75%)

ns- statistically insignificant (p&gt;0.05)

Association Declaration of Helsinki regarding ethical conduct of research involving human subjects. From all participants involved in this study informed written consent was collected.

## Results


Clinical and biochemical characteristics of the study group were presented in Tables 1 and 2. All variables showed statistically significant gender differences. In women significantly higher percentage of

fat mass, HDL-cholesterol, and apoAI concentrations were found. In men higher values of BMI, WHR, waist circumference, blood pressure, and almost twofold higher level of visceral fat were observed. In addition men showed significantly higher fasting glucose, insulin, HOMA-IR, triglycerides, non-HDL-C, and apoB:apoAI. Serum adiponectin and visfatin concentrations varied at 4.4–29.3 ng/mL and 1.9–36.3 ng/mL, respectively. Median adiponectin and visfatin concentrations were only slightly higher in women compared to men.

Correlation analysis performed in the whole study group showed a significant moderate inverse relation-

**Table 3.** Correlation of adiponectin and visfatin with selected variables (R-coefficient values; grey fields — results statistically significant  $p < 0.05$ )

Variables	All (n=60)		Women (n=30)		Men (n=30)	
	Adiponectin	Visfatin	Adiponectin	Visfatin	Adiponectin	Visfatin
BMI	-0.46	-0.33	-0.35	-0.32	-0.50	-0.37
Waist	-0.43	-0.30	-0.46	-0.36	-0.48	-0.41
WHR	-0.32	-0.19	-0.22	-0.25	-0.37	-0.20
CRP	-0.30	-0.23	-0.46	-0.21	-0.17	-0.24
Insulin	-0.34	-0.34	-0.20	-0.28	-0.36	-0.39
HOMA-IR	-0.38	-0.34	-0.24	-0.31	-0.41	-0.37
TC	-0.13	0.05	0.30	0.32	-0.43	-0.21
LDL-C	-0.19	0.01	0.22	0.31	-0.44	-0.24
HDL-C	0.34	0.18	0.33	0.16	0.26	0.21
non-HDL-C	-0.22	-0.01	0.22	0.31	-0.46	-0.26
apoA1	0.27	0.13	0.29	0.07	0.14	0.18
Fat mass %	-0.48	-0.38	-0.61	-0.33	-0.78	-0.65
Visceral fat	-0.68	-0.41	-0.64	-0.42	-0.77	-0.47



**Figure 1.** Prevalence of subjects in the groups determined by the values of adiponectin and CRP.

ship of adiponectin and visfatin with the percentage of fat mass, visceral fat, BMI, and waist circumference, whereas the inverse correlation with HOMA-IR and insulin was weak (Table 3).


Adiponectin was weakly inversely related to WHR and CRP ( $R = -0.30$ ;  $p = 0.022$ ), but a positive correlation was observed with HDL-C ( $R = 0.34$ ;  $p = 0.009$ ) and apoA1 ( $R = 0.27$ ;  $p = 0.002$ ).

Visfatin, similarly to adiponectin, showed a weak negative correlation with BMI, waist circumference, HOMA-IR, and body composition parameters: percentage fat mass ( $R = -0.38$ ;  $p = 0.003$ ) and visceral fat ( $R = -0.41$ ;  $p = 0.001$ ).

In men a stronger relationship of adiponectin and visfatin with anthropometric parameters, percentage fat mass, and visceral fat was found compared to women. Similarly, in men a significant, weak, negative correlation was observed between both adipocytokines and HOMA-IR and insulin. Only in men did select lipid parameters correlate significantly with adiponectin: TC ( $R = -0.43$ ;  $p = 0.017$ ), LDL-C ( $R = -0.44$ ;  $p = 0.015$ ) and non-HDL-C ( $R = -0.46$ ;  $p = 0.011$ ).

Interestingly, a significant correlation of adiponectin with CRP was found only in women ( $R = -0.46$ ;  $p = 0.01$ ).

In further analysis, subjects were divided into three groups according to tertiles of adiponectin and visfatin



**Figure 2.** Prevalence of subjects in the groups determined by the values of adiponectin and apoB.

concentrations. For adiponectin, the concentration ranges were: 4.43–8.69 (first tertile), 8.70–12.58 (second tertile), and 12.59–29.33 (third tertile) ng/mL. For visfatin, the distribution in tertiles was as follows: 1.86–9.58 (first tertile), 9.59–18.86 (second tertile), and 18.87–36.29 (third tertile) ng/mL. In subsequent adiponectin tertiles, a significant decrease in values of BMI ( $p = 0.02$ ), waist circumference ( $p = 0.002$ ), level of visceral fat ( $p < 0.001$ ), and insulin concentration ( $p = 0.018$ ) were observed (data not presented). For visfatin, similar trends were found only with the level of visceral fat ( $p < 0.01$ ) and triglycerides ( $p = 0.03$ ).

With the increase in adiponectin concentration the number of subjects with low CRP  $< 1$  mg/L significantly rose ( $p < 0.05$ ; Figure 1). An analogous relationship was observed for visfatin (data not presented). Moreover, the highest number of subjects with elevated apoB  $\geq 100$  mg/dL was found at the lowest adiponectin concentrations (Figure 2).

## Discussion

The analysis of body composition, especially the level of visceral fat, and laboratory markers of chronic inflammation, for example adipocytokines, may be useful for a more complete assessment of the risk of insulin resistance and cardiovascular diseases [8–9]. Despite the fact that the problems of obesity and metabolic syndrome have been discussed for years, the determination of adiponectin, visfatin, and body composition are still relatively rarely used in clinical practice to assess cardiometabolic risk.

In this study, no significant differences in adiponectin and visfatin concentrations were found for women and men; however, median concentrations were slightly higher in women. Cnop et al. observed significantly

higher adiponectin concentrations in women compared to men ( $7.4 \pm 2.9$  vs.  $5.4 \pm 2.3$  ng/mL;  $p < 0.001$ ) [10]. This phenomenon is explained by a higher percentage of adipose tissue in the females.

Yamamoto et al. showed a significant relationship between adiponectin levels and the value of arterial pressure, while Patel et al. did not observe such a correlation [11–12]. Yamamoto et al., in a group of 967 subjects aged 30–65 years, also found negative correlation of adiponectin concentration with BMI, insulin concentration, TC, TG, LDL-C, and insulin resistance index HOMA-IR and a positive correlation with HDL cholesterol level [11].

In several studies on obese subject with metabolic syndrome a negative correlation was found between adiponectin concentration and waist circumference [13–14], as well as with insulin resistance [15]. Interestingly, an inverse correlation between adiponectin and CRP was observed in a group of 312 men over 50 years of age [16], whereas in our study such a correlation was observed only in women. Our observation is based on the results from a small group of men, which is a limitation of this study and could influence the correlation analysis.

Adiponectin concentrations were related most of all with the indices of body fat composition, which indicates the important role of low concentrations of adiponectin in the pathogenesis of obesity, as well as its subsequent cardiometabolic complications.

The importance of visfatin in the pathogenesis of obesity and metabolic syndrome has not been clearly defined so far, and some other studies have yielded conflicting results. Fukuhara et al. showed significant correlation between visfatin concentration and the level of visceral fat and percentage of adipose tissue [17], whereas in a study by Berndt et al. no significant relationship was found between visfatin concentration and adipose tissue, as well as with insulin and BMI

[18]. Others showed a correlation between visfatin concentration with waist circumference and diastolic blood pressure and no significant dependence on BMI, HDL-C, and triglycerides [19]. In our study, moderate and weak negative correlations were observed between visfatin concentration and BMI, waist circumference, HOMA-IR, and, similarly to adiponectin, fat mass and level of visceral fat.

Controversial data in recent years indicate the potential role of visfatin in the pathogenesis of atherosclerosis and cardiovascular disease. They show that ox-LDL cause an increase in the expression of visfatin in cultured monocytes. Its high expression is also exhibited by macrophages in unstable atherosclerotic plaques; hence, visfatin may play a role in the destabilisation of atherosclerotic plaque. Its elevated concentrations are observed in groups of patients with unstable coronary disease (compared to stable disease) and after ischaemic stroke [20]. A study by Lim et al. conducted on mice showed that after the ischaemic event bolus administration of high concentration of visfatin reduced the size of the infarction [21]. Therefore, it seems that the increase in blood visfatin concentration in atherosclerosis and cardiovascular complications may be the result of a compensation mechanism associated with the induction of inflammation and vascular damage.

Based on the analysis of prospective population-based studies, it was clearly stated that hypoadiponectinaemia is a significant risk factor for cardiovascular disease and metabolic syndrome. In a study of 577 patients aged 25–74 years, a significant association of low adiponectin concentration on cardiovascular disease was observed, resulting in a negative effect on the metabolism of fatty acids directly involved in the development of hypertension [22]. Kumada et al. found significantly lower adiponectin level in a group of 225 men aged 40–69 years after coronarography, compared to the control group (4.7 ng/mL vs. 5.9 ng/mL,  $p < 0.001$ ), which proves that hypoadiponectinaemia was significantly and independently associated with the onset of ischaemic heart disease (IHD;  $p < 0.008$ ) [23]. In this study, subjects were divided according to quartiles of adiponectin concentrations. In the first quartile ( $< 4$  ng/mL), the risk of IHD was more than 2.5-fold higher than in the fourth quartile ( $> 7$  ng/mL), regardless of other risk factors (OR = 2.051; CI 95% 1.288–4.951 vs. OR = 0.749; 95% CI 0.392–1.418). Mohan et al. showed that adiponectin levels were significantly lower in patients with MetS compared to the control group (men: 5.0 vs. 6.8 ng / mL;  $p = 0.01$ ; women: 6.5 vs. 9.9 ng/mL;  $p = 0.001$ ). The analysis of the relationship showed a strong negative relationship between the concentration of adiponectin and the prob-

ability of the onset of metabolic syndrome in the study group ( $p < 0.001$ ) [24]. In our study, the highest prevalence of subject with CRP  $< 1$  mg/L, which reflects low relative risk of cardiovascular disease, was observed in the third adiponectin tertile, while an increased number of subjects with elevated apoB  $\geq 100$  mg/dL was found in the first tertile. This might indicate that in apparently healthy, non-obese individuals low adiponectin levels are associated with low-grade inflammation and dyslipidaemia, which increases cardiometabolic risk.

Considering the results of our own study and the presented relationships between adiponectin and visfatin concentration with select parameters of body composition, as well as biochemical risk factors for metabolic syndrome and cardiovascular diseases, it seems that the determination of these adipocytokines may be clinically useful in the more accurate assessment of possible cardiometabolic disorders in young, healthy people. However, due to the limitation of the study (small study group) the predictive value of both adipocytokines should be confirmed in a large population-based study.

**Authors' conflict of interest disclosure:** The authors state that there are no conflicts of interest regarding the publication of this article.

### List of abbreviations

apoAI — apolipoprotein AI  
 apoB — apolipoprotein B  
 BIA — bioelectrical impedance analysis  
 BMI — body mass index  
 CRP — C-reactive protein  
 DBP — diastolic blood pressure  
 ELISA — enzyme-linked immunosorbent assay  
 HOMA-IR — homeostatic model assessment-insulin resistance  
 HDL-C — high-density lipoprotein cholesterol  
 IHD — ischaemic heart disease  
 IL-6 — interleukin 6  
 IL-1 $\beta$  — interleukin 1 $\beta$   
 LDL-C — low-density lipoprotein cholesterol  
 non-HDL-C — non-high-density lipoprotein cholesterol  
 PBEF / NAMPT — B-cell colony-enhancing factor, visfatin  
 PCT — procalcitonin  
 SBP — systolic blood pressure  
 TC — total cholesterol  
 TG — triglycerides  
 TNF- $\alpha$  — tumor necrosis factor  $\alpha$   
 WHR — waist-to-hip ratio

## References

1. World Health Organization. The challenge of obesity in the WHO European Region. Fact sheet EURO. 2005; 13: 1–4.
2. Zhang LiQ, Heruth DP, Ye SQ. Nicotinamide Phosphoribosyltransferase in Human Diseases. *J Bioanal Biomed*. 2011; 3: 13–25, doi: [10.4172/1948-593X.1000038](https://doi.org/10.4172/1948-593X.1000038), indexed in Pubmed: [22140607](https://pubmed.ncbi.nlm.nih.gov/22140607/).
3. jr VT, Senolt L, Hulejova H, et al. Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis? *Biomedical Papers*. 2014, doi: [10.5507/bp.2014.012](https://doi.org/10.5507/bp.2014.012).
4. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun*. 1999; 257(1): 79–83, indexed in Pubmed: [10092513](https://pubmed.ncbi.nlm.nih.gov/10092513/).
5. Olszok J, Wyganowska A, Tarabura-Dragon J, et al. Selected adipocytokines and their potential role in the control of the course of chronic hepatitis B and C. *Annales Academiae Medicae Silesiensis*. 2015; 69: 1–7, doi: [10.18794/aams/23858](https://doi.org/10.18794/aams/23858).
6. Dąbrowska M, Szydłarska D, Bar-Andziak E. Adiponektyna a insulinooporność i miażdżyca. *Endokrynologia, Otyłość i Zaburzenia Przemiany Materii*. 2011; 7(3): 186–189.
7. Tanita® official website Available at: <https://www.tanita.com/en/> [cited: 01.03.2018]. <https://www.tanita.com/en/> [cited: 01.03.2018].
8. Musialik K. Wybrane wykładniki stanu zapalnego u pacjentów z zespołem metabolicznym. *Przegląd Kardiometaboliczny*. 2012; 7: 31.
9. Albu A, Delia L. Adipokines, systemic inflammation and exercise; Palestrica of the third millennium. *Civilization and Sport*. 2015; 16(3): 257–261.
10. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia*. 2003; 46(4): 459–469, doi: [10.1007/s00125-003-1074-z](https://doi.org/10.1007/s00125-003-1074-z), indexed in Pubmed: [12687327](https://pubmed.ncbi.nlm.nih.gov/12687327/).
11. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. *Clin Sci (Lond)*. 2002; 103(2): 137–142, doi: [10.1042/](https://doi.org/10.1042/), indexed in Pubmed: [12149104](https://pubmed.ncbi.nlm.nih.gov/12149104/).
12. Patel JV, Lim HS, Hughes EA, et al. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk? *J Hum Hypertens*. 2007; 21(1): 1–4, doi: [10.1038/sj.jnh.1002078](https://doi.org/10.1038/sj.jnh.1002078), indexed in Pubmed: [16871286](https://pubmed.ncbi.nlm.nih.gov/16871286/).
13. Bogdański P, Iciek J, Musialik- Pupek D. Wpływ regularnej aktywności fizycznej na stężenie adiponektyny u otyłych kobiet z zespołem metabolicznym. *Endokrynologia, Otyłość i Zaburzenia Przemiany Materii*. 2011; 7(4): 213.
14. Foremska- Ic, Kubacka E, Łuczak- Kujawska M, Musialik- Pupek D. Ocena stężenia adiponektyny u pacjentów z otyłością prostą. *Forum Zaburzeń Metabolicznych*. 2013; 4(1): 43–48.
15. Kadowaki T. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *Journal of Clinical Investigation*. 2006; 116(7): 1784–1792, doi: [10.1172/jci29126](https://doi.org/10.1172/jci29126).
16. Paschalis-Purtak K, Pucilowska B, Janas J, et al. Adiponectin and leptin plasma concentrations in men with coronary artery disease with and without hypertension. *Nadciśnienie Tętnicze*. 2009; 13(2): 74–81.
17. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science*. 2005; 307(5708): 426–430, doi: [10.1126/science.1097243](https://doi.org/10.1126/science.1097243), indexed in Pubmed: [15604363](https://pubmed.ncbi.nlm.nih.gov/15604363/).
18. Böttcher Y, Teupser D, Enigk B, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. *Diabetes*. 2005; 54(10): 2911–2916, indexed in Pubmed: [16186392](https://pubmed.ncbi.nlm.nih.gov/16186392/).
19. Foremska- Ic, Hoffmann K, Musialik- Pupek D. Ocena osoczowego stężenia wifafatyny u chorych z zespołem metabolicznym i samoistnym nadciśnieniem tętniczym. *Nadciśnienie tętnicze*. 2009; 13(4): 258–262.
20. Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, et al. Visfatin, glucose metabolism and vascular disease: a review of evidence. *Diabetol Metab Syndr*. 2010; 2: 21, doi: [10.1186/1758-5996-2-21](https://doi.org/10.1186/1758-5996-2-21), indexed in Pubmed: [20346149](https://pubmed.ncbi.nlm.nih.gov/20346149/).
21. Lim SY, Davidson SM, Paramanathan AJ, et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. *J Cell Mol Med*. 2008; 12(4): 1395–1403, doi: [10.1111/j.1582-4934.2008.00332.x](https://doi.org/10.1111/j.1582-4934.2008.00332.x), indexed in Pubmed: [18400051](https://pubmed.ncbi.nlm.nih.gov/18400051/).
22. Hui E, Xu A, Chow WS, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. *Hypertension*. 2007; 49(6): 1455–1461, doi: [10.1161/HYPERTENSION-107.086835](https://doi.org/10.1161/HYPERTENSION.107.086835), indexed in Pubmed: [17452504](https://pubmed.ncbi.nlm.nih.gov/17452504/).
23. Kumada M, Kihara S, Sumitsuiji S, et al. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. *Arterioscler Thromb Vasc Biol*. 2003; 23(1): 85–89, indexed in Pubmed: [12524229](https://pubmed.ncbi.nlm.nih.gov/12524229/).
24. Mohan V, Deepa R, Pradeepa R, et al. Association of low adiponectin levels with the metabolic syndrome--the Chennai Urban Rural Epidemiology Study (CURES-4). *Metabolism*. 2005; 54(4): 476–481, doi: [10.1016/j.metabol.2004.10.016](https://doi.org/10.1016/j.metabol.2004.10.016), indexed in Pubmed: [15798954](https://pubmed.ncbi.nlm.nih.gov/15798954/).